Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance

[1]  M. Fabbri,et al.  Noncoding RNA therapeutics — challenges and potential solutions , 2021, Nature reviews. Drug discovery.

[2]  I. Proietti,et al.  Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review , 2020, Cancers.

[3]  Xinxin Yang,et al.  Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles , 2020, International journal of nanomedicine.

[4]  C. Robert.  A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[5]  Hong Zheng,et al.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma , 2020, Frontiers in Oncology.

[6]  A. Tackett,et al.  Current state of melanoma diagnosis and treatment , 2019, Cancer biology & therapy.

[7]  D. Olteanu,et al.  Photodynamic Therapy in Melanoma - Where do we Stand? , 2019, Current medicinal chemistry.

[8]  J. Gershenwald,et al.  The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.

[9]  P. Soares,et al.  Melanoma treatment in review , 2018, ImmunoTargets and therapy.

[10]  Yvonne Tay,et al.  Noncoding RNA:RNA Regulatory Networks in Cancer , 2018, International journal of molecular sciences.

[11]  J. Shay,et al.  Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma , 2018, Oncogene.

[12]  G. Tse,et al.  Long non‐coding RNAs in melanoma , 2018, Cell proliferation.

[13]  L. Akslen,et al.  Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma , 2017, British Journal of Cancer.

[14]  M. Askarian-Amiri,et al.  Signaling Pathways in Melanogenesis , 2016, International journal of molecular sciences.

[15]  Stefan Van Aelst,et al.  Melanoma addiction to the long non-coding RNA SAMMSON , 2016, Nature.

[16]  M. Lamberti,et al.  Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment , 2015, Tumor Biology.

[17]  J. Malvehy,et al.  Update in genetic susceptibility in melanoma. , 2015, Annals of translational medicine.

[18]  D. Schadendorf,et al.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.

[19]  A. Adjei,et al.  The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.

[20]  M. Bosenberg,et al.  Melanoma metastasis: new concepts and evolving paradigms , 2014, Oncogene.

[21]  P. Ascierto,et al.  The role of MEK inhibitors in the treatment of metastatic melanoma , 2014, Current opinion in oncology.

[22]  B. Bedogni,et al.  Notch signaling in melanoma: interacting pathways and stromal influences that enhance Notch targeting , 2014, Pigment cell & melanoma research.

[23]  G. Gibney,et al.  NRAS mutant melanoma: biological behavior and future strategies for therapeutic management , 2013, Oncogene.

[24]  J. Bowling,et al.  Dermoscopic evaluation of nodular melanoma. , 2013, JAMA dermatology.

[25]  M. Czyz,et al.  Anti-apoptotic proteins on guard of melanoma cell survival. , 2013, Cancer letters.

[26]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[27]  A. Tymińska,et al.  Skin melanocytes: biology and development , 2013, Postepy dermatologii i alergologii.

[28]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[29]  Jamie K Teer,et al.  Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma , 2012, BMC Genomics.

[30]  V. Setaluri,et al.  Shining Light on Skin Pigmentation: The Darker and the Brighter Side of Effects of UV Radiation † , 2012, Photochemistry and photobiology.

[31]  C. Ng,et al.  NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.

[32]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[33]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[34]  Qihong Huang,et al.  Genomics screens for metastasis genes , 2012, Cancer and Metastasis Reviews.

[35]  G. Botti,et al.  BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  F. Marincola,et al.  The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.

[37]  F. Kelleher,et al.  Targeting NRAS in Melanoma , 2012, Cancer journal.

[38]  A. Ashworth,et al.  Whole genome sequencing of matched primary and metastatic acral melanomas. , 2012, Genome research.

[39]  P. Lopez-Bergami.  The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma , 2011, Pigment cell & melanoma research.

[40]  K. Flaherty,et al.  BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.

[41]  M. Bosenberg,et al.  Decoding Melanoma Metastasis , 2010, Cancers.

[42]  H. Tsao,et al.  Pathways to melanoma. , 2010, Seminars in cutaneous medicine and surgery.

[43]  L. Chin,et al.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis , 2010, Oncogene.

[44]  N. Sharpless,et al.  Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation , 2010, Melanoma research.

[45]  T. V. D. van der Cammen,et al.  [Melanomas more serious in the elderly]. , 2010, Nederlandsch tijdschrift voor geneeskunde.

[46]  L. Chin,et al.  Integrative Genome Comparison of Primary and Metastatic Melanomas , 2010, PloS one.

[47]  R. Auerbach,et al.  Immunotherapy for Melanoma , 1973 .

[48]  N. Stoecklein,et al.  Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis , 2010, International journal of cancer.

[49]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[50]  Mingming Jia,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..

[51]  D. Fisher,et al.  Transcriptional regulation in melanoma. , 2009, Hematology/oncology clinics of North America.

[52]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[53]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[54]  Harold Varmus,et al.  Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.

[55]  S Grover,et al.  Fitzpatrick's Dermatology in General Medicine , 2008 .

[56]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[57]  Kedar S Vaidya,et al.  Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. , 2007, Journal of the National Cancer Institute.

[58]  L. Chin,et al.  Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene , 2006, Cell.

[59]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[60]  Noreen Heer Nicol,et al.  Anatomy and Physiology of the Skin , 2005, Dermatology nursing.

[61]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[62]  Tobias Pincock.  Fitzpatrick's Dermatology in General Medicine , 2003 .

[63]  L. Freedman,et al.  Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. , 2003, Cancer research.

[64]  E. Price,et al.  β-Catenin–induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor , 2002, The Journal of Cell Biology.

[65]  J. Kanitakis,et al.  Anatomy, histology and immunohistochemistry of normal human skin. , 2002, European journal of dermatology : EJD.

[66]  C. Wolf‐peeters,et al.  Loss of Membranous Expression of β-Catenin Is Associated with Tumor Progression in Cutaneous Melanoma and Rarely Caused by Exon 3 Mutations , 2002, Modern Pathology.

[67]  S. Schiffmann,et al.  The Metastasis Suppressor Gene KiSS-1 Encodes Kisspeptins, the Natural Ligands of the Orphan G Protein-coupled Receptor GPR54* , 2001, The Journal of Biological Chemistry.

[68]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[69]  大堀 理,et al.  Memorial Sloan-Kettering Cancer Center , 2020, Definitions.

[70]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[71]  J M Trent,et al.  KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. , 1996, Journal of the National Cancer Institute.

[72]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[73]  L. Alonso,et al.  miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. , 2018, Cancer research.

[74]  James S Goydos,et al.  Acral Lentiginous Melanoma. , 2016, Cancer treatment and research.

[75]  M. Sheikh,et al.  Melanoma: Molecular Pathogenesis and Therapeutic Management. , 2014, Molecular and cellular pharmacology.

[76]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[77]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .